0001127602-22-022683.txt : 20220919
0001127602-22-022683.hdr.sgml : 20220919
20220919163936
ACCESSION NUMBER: 0001127602-22-022683
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220915
FILED AS OF DATE: 20220919
DATE AS OF CHANGE: 20220919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Basil Michelle L
CENTRAL INDEX KEY: 0001699629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14041
FILM NUMBER: 221251001
MAIL ADDRESS:
STREET 1: HAEMONETICS CORPORATION
STREET 2: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HAEMONETICS CORP
CENTRAL INDEX KEY: 0000313143
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042882273
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0401
BUSINESS ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 7818487100
MAIL ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-09-15
0000313143
HAEMONETICS CORP
HAE
0001699629
Basil Michelle L
125 SUMMER STREET
BOSTON
MA
02110
1
EVP and General Counsel
Common Stock
2022-09-15
4
M
0
11154
38.43
A
51789
D
Common Stock
2022-09-15
4
M
0
14231
41.64
A
66020
D
Common Stock
2022-09-15
4
M
0
3173
56.57
A
69193
D
Common Stock
2022-09-15
4
S
0
27769
77.76
D
41424
D
Common Stock
2022-09-15
4
S
0
6029
78.50
D
35395
D
Non-qualified Stock Option (Right to Buy)
38.43
2022-09-15
4
M
0
11154
0
D
2018-03-06
2024-03-06
Common Stock
11154
3464
D
Non-qualified Stock Option (Right to Buy)
41.64
2022-09-15
4
M
0
14231
0
D
2018-06-06
2024-06-06
Common Stock
14231
4213
D
Non-qualified Stock Option (Right to Buy)
56.57
2022-09-15
4
M
0
3173
0
D
2028-05-18
Common Stock
3173
13564
D
Transaction pursuant to an existing 10b5-1 trading plan.
This number includes unvested restricted stock units ("RSUs") previously reported.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive.
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
/s/ Michelle L. Basil
2022-09-19